FUTIBATINIB: 161 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
161
Total FAERS Reports
38 (23.6%)
Deaths Reported
60
Hospitalizations
161
As Primary/Secondary Suspect
2
Life-Threatening
Jul 28, 2025
FDA Approved
TAIHO PHARMACEUTICAL CO., LTD.
Manufacturer
Prescription
Status
Drug Class: Breast Cancer Resistance Protein Inhibitors [MoA] · Manufacturer: TAIHO PHARMACEUTICAL CO., LTD. · FDA Application: 214801 ·
Patent Expires: Nov 5, 2039 · First Report: 20200101 · Latest Report: 20250623
What Are the Most Common FUTIBATINIB Side Effects?
#1 Most Reported
Death
30 reports (18.6%)
#2 Most Reported
Diarrhoea
29 reports (18.0%)
#3 Most Reported
Hyperphosphataemia
22 reports (13.7%)
All FUTIBATINIB Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 30 | 18.6% | 30 | 9 |
| Diarrhoea | 29 | 18.0% | 4 | 13 |
| Hyperphosphataemia | 22 | 13.7% | 6 | 6 |
| Nausea | 21 | 13.0% | 9 | 12 |
| Disease progression | 20 | 12.4% | 5 | 6 |
| Dry mouth | 18 | 11.2% | 4 | 9 |
| Fatigue | 18 | 11.2% | 6 | 8 |
| Off label use | 16 | 9.9% | 5 | 4 |
| Vomiting | 15 | 9.3% | 5 | 11 |
| Dry eye | 13 | 8.1% | 0 | 5 |
| Constipation | 12 | 7.5% | 2 | 8 |
| Decreased appetite | 12 | 7.5% | 1 | 7 |
| Neuropathy peripheral | 12 | 7.5% | 1 | 7 |
| Asthenia | 11 | 6.8% | 4 | 7 |
| Dehydration | 11 | 6.8% | 5 | 8 |
| Blood phosphorus increased | 10 | 6.2% | 2 | 6 |
| Dry skin | 10 | 6.2% | 0 | 5 |
| Onychomadesis | 10 | 6.2% | 0 | 4 |
| Pain in extremity | 10 | 6.2% | 1 | 4 |
| Stomatitis | 10 | 6.2% | 3 | 5 |
Who Reports FUTIBATINIB Side Effects? Age & Gender Data
Gender: 51.3% female, 48.7% male. Average age: 61.8 years. Most reports from: US. View detailed demographics →
Is FUTIBATINIB Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2020 | 1 | 1 | 1 |
| 2021 | 3 | 0 | 3 |
| 2022 | 14 | 2 | 10 |
| 2023 | 25 | 9 | 16 |
| 2024 | 22 | 10 | 10 |
| 2025 | 8 | 1 | 3 |
What Is FUTIBATINIB Used For?
| Indication | Reports |
|---|---|
| Cholangiocarcinoma | 77 |
| Product used for unknown indication | 23 |
| Oesophageal carcinoma | 11 |
| Bile duct cancer | 10 |
FUTIBATINIB vs Alternatives: Which Is Safer?
FUTIBATINIB vs GABAPENTIN
FUTIBATINIB vs GABAPENTIN ENACARBIL
FUTIBATINIB vs GADAVIST
FUTIBATINIB vs GADOBENATE DIMEGLUMINE
FUTIBATINIB vs GADOBUTROL
FUTIBATINIB vs GADODIAMIDE
FUTIBATINIB vs GADOLINIUM
FUTIBATINIB vs GADOPENTETATE DIMEGLUMINE
FUTIBATINIB vs GADOPICLENOL
FUTIBATINIB vs GADOTERATE MEGLUMINE
Other Drugs in Same Class: Breast Cancer Resistance Protein Inhibitors [MoA]
Official FDA Label for FUTIBATINIB
Official prescribing information from the FDA-approved drug label.